Potential With Cabozantinib Plus Nivolumab in Advanced RCC
Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, senior physician, instructor in medicine, Harvard Medical School, discusses the goals of the phase III CheckMate-9ER trial, which is evaluating cabozantinib combined with nivolumab in previously untreated patients with advanced or metastatic renal cell carcinoma (RCC).
Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, senior physician, instructor in medicine, Harvard Medical School, discusses the goals of the phase III CheckMate-9ER trial, which is evaluating cabozantinib (Cabometyx) combined with nivolumab (Opdivo) in previously untreated patients with advanced or metastatic renal cell carcinoma (RCC).
There has been a revolution in RCC treatment over the last couple of years, starting with the immunotherapy combination of nivolumab and ipilimumab (Yervoy) in the CheckMate-214 trial. Cabozantinib is an intriguing multikinase inhibitor that has also demonstrated benefit in patients with both treatment-naïve and previously treated disease, McGregor says.
Building upon the activity with these types of agents in the frontline setting, the CheckMare-9ER trial is looking at the combination of cabozantinib and nivolumab compared with sunitinib (Sutent) to determine if the combination can improve response rates and outcomes in the frontline setting.
Interpreting Trial Data on Tolerability in Third-Line mRCC Regimens
November 28th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro C. Barata, MD, MSc, and participants discussed dosing and toxicity issues related to tivozanib and lenvatinib/everolimus in a patient who has received 2 prior lines of therapy for metastatic clear cell renal cell carcinoma.
Read More
Park Considers Long-Term Data for Frontline Metastatic ccRCC Treatment
November 24th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Chandler Park, MD, reviewed the latest updates of the pivotal trials of frontline combination therapies for advanced clear cell renal cell carcinoma.
Read More
